HYP 2090 PTSA
Alternative Names: HY-0002; HY-0002a; HYP-2090-PTSA; HYP-2ALatest Information Update: 28 Feb 2026
At a glance
- Originator Sichuan Huiyu Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; KRAS protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Colorectal cancer; Non-small cell lung cancer
- No development reported Cancer
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for research development in Cancer in Europe (PO)
- 29 Jan 2026 Phase-I clinical trials in Colorectal cancer in China (PO) prior to January 2026 (Sichuan Huiyu Pharmaceuticals pipeline, January 2026)
- 29 Jan 2026 Phase-I clinical trials in Non-small cell lung cancer in China (PO) prior to January 2026 (Sichuan Huiyu Pharmaceuticals pipeline, January 2026)